X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Integrilin-Generic (eptifibatide) is a USFDA approved platelet aggregation inhibitor, which is indicated for the treatment of patients with acute coronary syndrome.
Lead Product(s): Eptifibatide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Integrilin-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
The company launched desmopressin acetate for injection in the United States as a therapeutic equivalent generic for DDAVP for treating is multi-indicated for patients with central diabetes insipidus, hemophilia A, and von willebrand’s disease (Type I).
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Rare Diseases and Disorders Product Name: DDAVP-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Lasix-Generic (furosemide) is a USFDA approved loop diuretic, which is indicated for the treatment of adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lasix-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
Emend-Generic(fosaprepitant) is a NK1 receptor antagonist, indicated in adults and pediatric patients aged 6 months & older along with other antiemetic agents, for the prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of chemotherapy.
Lead Product(s): Fosaprepitant
Therapeutic Area: Gastroenterology Product Name: Emend-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
Angiomax-Generic (bivalirudin) is a direct thrombin inhibitor, which is now launched in the US market. It is indicated for treatment of patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
Lead Product(s): Bivalirudin
Therapeutic Area: Hematology Product Name: Angiomax-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Alkeran-Generic (melphalan hydrochloride) is a DNA alkylating agent of the bischloroethylamine type. It is approved for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Lead Product(s): Melphalan Hydrochloride
Therapeutic Area: Oncology Product Name: Alkeran-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
